

II Reunión Investigación Traslacional en Melanoma

03 NOVIEMBRE 2016

Hospital Universitario Dexeus -
Grupo Quirón Salud
Auditorio

C/ Sabino Arana, 5-19
08028 Barcelona

II Reunión Investigación Traslacional en Melanoma

PROGRAMA CIENTÍFICO

03 NOVIEMBRE 2016

Hospital Universitario Dexeus -
Grupo Quirón Salud
Auditorio

BARCELONA



Organizado por:



Con el Aval Científico de:



Solicitada acreditación:



Secretaría Técnica:



M FAR

secretaria@groupgem.org
Tel. 93 434 44 12

GEM agradece a Teresa González Cao la donación desinteresada de la obra de la portada.

Organizado por:



Coordinadora Científica:
Dra. María González Cao

TRANSLATIONAL MEETING
THURSDAY 03 NOVEMBER 2016 JUEVES 03 NOVIEMBRE 2016
SCIENTIFIC PROGRAM

09.15 h	WELCOME Dr. Salvador Martín Algarra, President GEM Dr. María González Cao, Meeting Coordinator	14.25 - 16.00 h	PART IV: Guess labs <i>The speakers will decide the title of their talks; 5 minutes questions after every talk</i> Chairman: Dr. Iván Márquez (Hospital Universitario Gregorio Marañón, Madrid) Dr. Eloisa Jantus (Hospital General de Valencia, Valencia)
09.20 - 11.45 h	PART I: Inspiring talks: virus, bacteria and cancer Chairman: Dr. Alfonso Berrocal (Hospital General Universitario, Valencia) Dr. Manel Juan Otero (Hospital Clínic, Barcelona)	14.25 - 14.45 h	Title to be defined Dr. Joan Seoane's group (Hospital Vall D'Hebron, Barcelona)
09:20 - 10.00 h	MICROBIOTA, VIRUS AND IMMUNE RESPONSE Overcoming mechanisms of resistance to cancer immunotherapy Dr. Thomas Gajewsky (University of Chicago Medical Center, Chicago)	14.50 - 15.10 h	Title to be defined Dr. Susana Puig's group (Hospital Clínic, Barcelona)
10.00 - 10.40h	Predictive biomarkers for immune resistance and combinatory therapies with anti-PD-1 and anti-PD-L1 antibodies Dr. Rafael Rosell (Translational Cancer Research Unit, Dexeus University Hospital - Quirón Group, Barcelona / Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona)	15.15 - 15.35 h	Molecular mechanisms of PD1-depedent T cell suppression Dr. David Escors's group (NavarraBiomed, Pamplona)
10.40- 11.20h	Targeted therapy and melanoma immunogenicity: a role for retroviruses? Dr. Claudia Wellbrock (Manchester Cancer Research Centre, Manchester)	15.40 -16.00h	Title to be defined Dr. J. Pedro Vaqué (Instituto de Investigación Marqués de Valdecilla, Santander)
11. 20-11.45h	Discussion	16.00-16.10 h	Dendritic cell targeted vaccine against melanoma Dr. Carmen Álvarez (Hospital Universitario Marqués de Valdecilla, Santander)
11.45 - 12.15 h	PART II: Science with and for society Chairman: Dr. Salvador Martín Algarra (Clínica Universidad de Navarra, Pamplona) Dr. Ainara Soria (Hospital Universitario Ramón y Cajal, Madrid)	16.10-16.35h	COFFEE BREAK
11.45 - 12.05h	Responsible Research & Innovation (RRI) Dr. Rosina Malagrida (Irsi Caixa, Barcelona)	16.35 - 14.25 h	PART V: Translational research in GEM <i>Talks about recent or ongoing studies; 5 minutes questions after every talk</i> Chairman: Dr. Ana Arance (Hospital Clínic, Barcelona) Dr. Virtudes Soriano (Instituto Valenciano de Oncología, Valencia) Dr. Imanol Arozarena (Navarrabiomed-Fundación Miguel Servet -IDISNA-, Pamplona)
12.05 - 12.15 h	Discussion	16.35 - 16.45 h	HIV and cancer: anti PD-1 treatment Dr. María Gonzalez-Cao (Translational Cancer Research Unit, Dexeus University Hospital-Quirón Group, Barcelona)
12.15 - 13.15 h	LUNCH	16.50 - 17.05 h	Nano String nCounter: predictive value for anti PD-1 drugs Dr. Aleix Prat (Hospital Clínic, Barcelona)
13:15 - 14.25 h	PART III: Practical issues Talks about specific techniques and results Chairman: Dr. Teresa Puértolas (Hospital Universitario Miguel Servet, Zaragoza) Dr. Enrique Espinosa (Hospital Universitario La Paz, Madrid)	17.10 - 17.25 h	Mechanism of resistance to BRAF inhibitors Dr. José Luis Manzano (Hospital Germans Trias I Pujol, Barcelona)
13.15 - 13.35 h	WES analysis and liquid biopsy: practical issues Dr. Leticia De Mattos Arruda (Cambridge, United Kingdom)	17.25 - 18.00 h	PART VI: From bench to the bed Chairman Dr. Salvador Martín Algarra (Clínica Universidad de Navarra, Pamplona)
13.35 - 13.55 h	cfDNA multiplex analysis platform Dr. Miguel Ángel Molina (Translational Cancer Research Unit, Dexeus University Hospital-Quirón Group, Barcelona)	17.25 - 18:00 h	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma Dr. Paul Lorigan (Institute of Cancer Sciences Faculty of Medical & Human Sciences University of Manchester)
13.55 - 14.15 h	RNA expression analysis: different sources and techniques Dr. Niky Karachaliou (Translational Cancer Research Unit, Dexeus University Hospital-Quirón Group, Barcelona)	18.10 - 18.30 h	CLOSING REMARKS Dr. Salvador Martín Algarra (Clínica Universidad de Navarra, Pamplona) Dr. Alfonso Berrocal (Hospital General Universitario de Valencia)
14.15 - 14.25 h	Discussion		